Tag: clinical development strategy

KPIs, Dashboards and Scorecards to Track Pricing, Reimbursement & HTA Interfaces KPIs, Dashboards and Scorecards to Track Pricing, Reimbursement & HTA Interfaces In today’s complex clinical research environment, characterized by regulatory frameworks such as ICH-GCP, FDA, EMA, and MHRA guidelines, the need for effective monitoring of key performance indicators (KPIs), dashboards, and scorecards is paramount….

Read More “KPIs, Dashboards and Scorecards to Track Pricing, Reimbursement & HTA Interfaces” »

Vendor, Site and Partner Negotiation Tactics Driven by Pricing, Reimbursement & HTA Interfaces Effective Vendor, Site and Partner Negotiation Tactics in Clinical Trials The landscape of clinical trials continues to evolve, particularly with the increasing emphasis on remote monitoring in clinical trials and cost management strategies. As operational complexities rise, clinical operations, regulatory affairs, and…

Read More “Vendor, Site and Partner Negotiation Tactics Driven by Pricing, Reimbursement & HTA Interfaces” »

Scenario Planning: Best-Case and Worst-Case Pricing, Reimbursement & HTA Interfaces Outlooks Best-Case and Worst-Case Pricing, Reimbursement & HTA Interfaces Outlooks in Clinical Trials In the rapidly evolving landscape of clinical trials, effective scenario planning is essential for anticipating and preparing for potential pricing, reimbursement, and Health Technology Assessment (HTA) outcomes. This comprehensive guide serves as…

Read More “Scenario Planning: Best-Case and Worst-Case Pricing, Reimbursement & HTA Interfaces Outlooks” »

Investor, Board and C-Suite Questions Around Pricing, Reimbursement & HTA Interfaces—Answered In the evolving landscape of clinical trials, particularly those involving paid virtual clinical trials, it is crucial for biopharmaceutical executives to have a solid grasp of pricing, reimbursement, and health technology assessment (HTA) interfaces. This article provides a step-by-step tutorial aimed at addressing comprehensive…

Read More “Investor, Board and C-Suite Questions Around Pricing, Reimbursement & HTA Interfaces—Answered” »

Future Trends in Clinical Trials: AI, RWE and New Business Models in Pricing, Reimbursement & HTA Interfaces The evolution of clinical trials is undergoing profound changes driven by innovative technologies and methodologies. Among these, Artificial Intelligence (AI) and Real-World Evidence (RWE) are emerging as pivotal elements influencing pricing, reimbursement, and Health Technology Assessment (HTA) processes….

Read More “Future Trends: AI, RWE and New Business Models in Pricing, Reimbursement & HTA Interfaces” »

Digital Tools and Analytics to Forecast and Monitor Pricing, Reimbursement & HTA Interfaces Digital Tools and Analytics to Forecast and Monitor Pricing, Reimbursement & HTA Interfaces Introduction to Digital Tools and Analytics in Clinical Trials The integration of digital tools into clinical trials is revolutionizing the way researchers forecast and monitor various essential components such…

Read More “Digital Tools and Analytics to Forecast and Monitor Pricing, Reimbursement & HTA Interfaces” »

Risk Scenarios and Sensitivity Analyses for Pricing, Reimbursement & HTA Interfaces The landscape of drug pricing, reimbursement, and Health Technology Assessment (HTA) has become increasingly complex, necessitating a thorough understanding of various risk scenarios and their implications for electronic data capture in clinical trials. This article serves as a step-by-step tutorial guiding clinical operations, regulatory…

Read More “Risk Scenarios and Sensitivity Analyses for Pricing, Reimbursement & HTA Interfaces” »

Regulatory and Policy Shifts Reshaping Pricing, Reimbursement & HTA Interfaces in the US, EU and UK Regulatory and Policy Shifts Reshaping Pricing, Reimbursement & HTA Interfaces in the US, EU and UK Introduction to the Evolving Landscape of Clinical Trials The biopharmaceutical and clinical research industry is undergoing substantial changes, particularly in the domains of…

Read More “Regulatory and Policy Shifts Reshaping Pricing, Reimbursement & HTA Interfaces in the US, EU and UK” »